Previous 10 | Next 10 |
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financia...
Goal of Partnership is to expand Avalon’s R&D pipeline to include innovative companion diagnostics in association with the company’s ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagno...
Shares of Avalon GloboCare (NASDAQ:AVCO) are trading ~7% higher at $0.60 in morning trade on Wednesday, after the company said it had expanded its intellectual property portfolio by jointly filing 16 new patent applications with various regulatory bodies. AVCO said the co-inventors of the new...
Co-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading glob...
Leveraging Avalon’s existing Flash-CAR TM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeutics Clinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a pot...
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSW...
Gainers: Insignia Systems (NASDAQ:ISIG) +83%.. Pop Culture (NASDAQ:CPOP) +24%. Regencell Bioscience RGC +20% BridgeBio Pharma BBIO +19%. Gamida Cell (NASDAQ:GMDA) +17%. ADDvantage Technologies (NASDAQ:AEY) +17%. Centogene (NASDAQ:CNTG) +14% Altamira Therapeu...
FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0 million of debt owed t...
Avalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design “QTY Code” technology with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2 , to accurately predict the 3D structures of protein receptors ...
Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences (BOKU) Vienna FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCa...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...